Icosavax…today announced the results from an end-to-end drug product investigation of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD). This investigation was initiated following the company’s Phase 1/2 topline interim data results in which the immunologic response observed for IVX-411 was inconsistent with expectations based on known data for the company’s platform and VLP technology.
…The RBD antigen component (Component A) of IVX-411 becomes unstable during manufacturing and subsequent storage at 2-8 °C…